Drug pricing probes pressure companies

| BY

Katherine Jo &clp articles

China's antitrust regulator has launched an official investigation campaign to unravel the complex supply and distribution networks of drugs and medical devices. Healthcare firms will need to ensure proper pricing conduct and prepare for the surveys and raids

The National Development and Reform Commission (NDRC) has formally launched a nationwide pricing investigation into China's pharmaceutical and medical devices industries.

The campaign, announced through the May 22 Circular on the Launch of a Dedicated Nationwide Review on the Pricing of Pharmaceuticals (Circular), runs from June 1 to October 31, 2016.

This premium content is reserved for
China Law & Practice Subscribers.

  • A database of over 3,000 essential documents including key PRC legislation translated into English
  • A choice of newsletters to alert you to changes affecting your business including sector specific updates
  • Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected]